ecrin-mdr-crcClinical2012Colorectal NeoplasmsColorectal Cancer MetastaticColorectal NeoplasmsColorectal Cancer MetastaticInterventionalhttps://newmdr.ecrin.org/Study/2130809France8IrinotecanLeucovorinAfliberceptFluorouracilECRIN MDRCompletedfalseColorectal Cancer MetastaticPrimary Objective: To evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those evaluated in the VELOUR trial [EFC10262, NCT00561470]) according to side effects prevention and management guidelines. Secondary Objective: To document the Health-Related Quality of Life (HRQL) of aflibercept in this participant population.2012-08-152130809NCT01670721U1111-1128-93252012-000048-89